A retrospective study of incidence of Guillain-Barre syndrome among adult patients treated with seven anti-SARS-CoV-2 vaccines
Latest Information Update: 28 Oct 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 01 Nov 2022 Results published in the European Journal of Neurology
- 28 Oct 2022 New trial record